PHASE-I STUDY OF METHYLACETYLENIC PUTRESCINE, AN INHIBITOR OF POLYAMINE BIOSYNTHESIS

被引：5

作者：

CORNBLEET, MA

KINGSNORTH, A

TELL, GP

HAEGELE, KD

JODEROHLENBUSCH, AM

SMYTH, JF

机构：

[1] MERRELL DOW RES INST,STRASBOURG,FRANCE

[2] UNIV EDINBURGH,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND

[3] UNIV EDINBURGH,DEPT SURG,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1989年 / 23卷 / 06期

关键词：

D O I：

10.1007/BF00435834

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：348 / 352

页数：5

共 20 条

[1] PHASE-I TRIAL AND PHARMACOKINETIC STUDIES OF ALPHA-DIFLUOROMETHYLORNITHINE - AN INHIBITOR OF POLYAMINE BIOSYNTHESIS [J].

ABELOFF, MD ;

SLAVIK, M ;

LUK, GD ;

GRIFFIN, CA ;

HERMANN, J ;

BLANC, O ;

SJOERDSMA, A ;

BAYLIN, SB .

JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (02) :124-130

[2]

BARTHOLEYNS J, 1984, CANCER RES, V44, P4972

[3] (2R,5R)-6-HEPTYNE-2,5-DIAMINE, AN EXTREMELY POTENT INHIBITOR OF MAMMALIAN ORNITHINE DECARBOXYLASE [J].

DANZIN, C ;

CASARA, P ;

CLAVERIE, N ;

METCALF, BW ;

JUNG, MJ .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 116 (01) :237-243

[4]

FREIREICH EMIL J., 1962, CANCER CHEMOTHER REPTS, V16, P183

[5]

HAEGELE KD, 1987, CANCER RES, V47, P890

[6]

HOLLTA E, 1981, BIOCHIM BIOPHYS ACTA, V677, P90

[7]

KINGSNORTH AN, 1986, ANN ROY COLL SURG, V68, P76

[8]

MADDOX AM, 1985, INVEST NEW DRUG, V3, P287

[9]

MAMONT PS, 1982, EUR J BIOCHEM, V123, P499

[10]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

← 1 2 →